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Abstract
Introduction—Appalachian Kentucky is recognized for elevated rates of cervical cancer, which 
exerts an undue burden in this medically underserved region. The purpose of this study was to 
examine the impact of an academic–community partnership, specifically a regional health 
department and a CDC Prevention Research Center, in conducting outreach aimed at improving 
Pap testing rates and examining barriers among under-screened women in Appalachian Kentucky. 
Differences between women with abnormal and negative results were also examined.
Methods—The Prevention Research Center provided technical assistance to the district health 
department that, in turn, hosted “Women’s Health Day” events at county health departments, 
providing incentives to women who had never had a Pap test or those who had not received one in 
at least 3 years to receive guideline-recommended screening.
Results—From 2011 to 2014, 317 women were screened for cervical cancer; data were analyzed 
in 2014. The mean age was 42.1 (SD=13.6) years. More than half (54.5%) of the sample reported 
high school as their highest level of education, and 57.7% had an annual household income of <
$25,000. The most commonly reported barriers to Pap testing were cost (28.4%) and lack of a 
perceived need for screening (25.6%). Approximately one in five (21.7%) women received 
abnormal Pap results.
Conclusions—As a result of this community–academic public health partnership and its shared 
resources, Appalachian Kentucky women received needed cervical cancer screening and 
appropriate follow-up for abnormal results, thereby increasing this population’s compliance with 
guideline-recommended screening.
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Introduction
Screening women for precancerous changes of the cervix via Pap testing has made cervical 
cancer one of the most preventable cancers in the U.S.1,2 Cervical cancer incidence and 
mortality rates continue to decrease annually in the U.S., yet an estimated 12,900 new cases 
and 4,100 related deaths will occur in 2015.3,4 The enduring burden of cervical cancer in the 
U.S. may be a result of the lack of adherence to recommended screenings, as screening rates 
have remained below national goals.5,6 For instance, low-income, medically underserved 
populations have consistently been under-screened for cervical cancer, including women in 
Appalachia.7,8 Appalachian women receive cervical cancer screenings less frequently than 
their non-Appalachian counterparts,8–10 which has been linked to screening barriers, 
including geographic isolation, cost, lack of insurance, and limited access to medical 
care.8,11–16
Lower screening rates in Appalachia is disconcerting given the elevated cervical cancer 
incidence and mortality in this region;11,13,16,17 these cancer disparities are further amplified 
in Kentucky.16–18 Kentucky Cancer Registry data indicate that Appalachian-designated 
counties reported higher cervical cancer incidence rates (9.5 per 100,000) than the rest of the 
state (8.4) from 2007 to 2011.19 Moreover, cervical cancer screening rates in Appalachian 
Kentucky are also lower than in other parts of Appalachia.10 Previous studies in 
Appalachian Kentucky found that more than 30% of women reported to be rarely (i.e., have 
not been screened within the past 5 years) or never screened for cervical cancer;9,20 in 
comparison, roughly 10% of U.S. women report to be rarely or never screened.21
To assist underserved women at risk for developing cervical cancer, the National Breast and 
Cervical Cancer Early Detection Program (NBCCEDP) provides funding to local and state 
health departments for the implementation of screening programs. These programs aim to 
remove screening barriers, such as cost and access to care, by providing Pap testing and 
follow-up care at little to no cost.22 Despite the availability of such programs, many 
underserved women are not utilizing them; from 2010 to 2012, less than 7% of NBCCEDP-
eligible women took part in the program.23 Low participation rates highlight the need for 
enhanced promotional efforts to reach program-eligible women, including the identification 
and characterization of women at risk for abnormal results.
To identify additional screening barriers and enhance awareness of existing screening 
programs for underserved women, efforts have increasingly focused on the development of 
academic–community partnerships.24 Partnerships enhance the ability of communities to 
meet screening needs with collective resources and increased capacity;25 they also serve as a 
mechanism for community-engaged research, which integrates evidence-based health 
promotion practices with extensive community knowledge.26 Ultimately, findings can be 
used to implement sustainable solutions that meet a community’s distinctive needs.27,28 
Such partnerships have been used in cervical cancer screening research in Appalachia 
focusing on faith-based organizations, utilization of lay health navigators, and adherence to 
follow-up services.12,14,15,29 The purpose of this study was twofold:
1. to examine the impact of an academic–community partnership, specifically a 
regional health department and a CDC Prevention Research Center (PRC), in 
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conducting outreach aimed at improving cervical cancer screening rates and 
examining barriers among under-screened women in a rural Appalachian area; and
2. to determine whether differences existed between women with an abnormal result 
and those with a negative result, as differences could potentially guide targeted 
efforts directed at women likely to have early-stage cervical cancer.
Methods
Academic–Community Partnership
In 2010, the University of Kentucky (UK)—with funding from the CDC PRC program—
formed the Rural Cancer Prevention Center (RCPC), which aims to address cancer 
disparities in a medically underserved, high-poverty area in Appalachian Kentucky. To 
inform actions within the community, the RCPC recruited local constituents for its 
Community Advisory Board (CAB), which consists of Kentucky River District Health 
Department (KRDHD) staff, cancer survivors, lay citizens, and representatives from local 
schools, faith-based organizations, and civic groups.
In 2011, a CAB member suggested that KRDHD host “Women’s Health Day” (WHD) 
events at each of its seven clinics. During these events, women who were due for a 
guideline-recommended cervical cancer screening would be offered free Pap testing, as 
previous evaluations revealed that many women in the area were guideline discordant (D 
Neace, KRDHD, personal communication, 2014). The events would also be used to promote 
and enroll women into the NBCCEDP-funded Kentucky Women’s Cancer Screening 
Program (KWCSP). CAB members were supportive of the proposal, and a collaborative 
agreement between the RCPC and KRDHD was established. The health department 
managed project implementation, survey development, participant recruitment, KWCSP 
promotion and enrollment, and data collection. Given the lower socioeconomic 
characteristics of the catchment area’s population,30 most of the WHD participants were 
eligible for free screening and follow-up services via the cancer screening program. 
Therefore, the majority of WHD-related costs were covered by program funding; the health 
department covered screening and follow-up services for women ineligible for KWCSP. The 
RCPC was responsible for assisting with promotional activities, data analysis, results 
dissemination, and participant incentives. The study protocol was approved by the UK and 
Kentucky Cabinet for Health and Family Services IRB.
Participant Recruitment
Prior to WHD, health department staff promoted the event during patient visits, 
advertisements were placed in local newspapers, and announcements were made on local 
radio stations. The health department hosted 29 of these events from October 2011 to May 
2014. To participate in the project, women had to be aged 18–65 years, eligible to receive 
health department services, and self-report not ever receiving a Pap test (classified as never 
screened) or within the past 3 years (classified as rarely screened). Women were not eligible 
to participate if they were currently pregnant, had a hysterectomy, or were previously 
diagnosed with cervical cancer.
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The WHD events began prior to the 2012 U.S. Preventive Services Task Force (USPSTF) 
cervical cancer screening guideline revisions.31 Accordingly, KRDHD followed 2003 
USPSTF guidelines, which recommended screening within 3 years of sexual debut or at age 
21 years, whichever came first, and routine screening at least every 3 years.32 KRDHD 
decided to follow the 2003 recommendations for the duration of the events to maintain 
continuity of the project. Thus, women aged 18–20 years were eligible for participation, and 
women outside of recommended guidelines (i.e., had not been screened within the past 3 
years) were classified as rarely screened.
Women’s Health Day Activities
At these events, health department staff provided education on women’s health issues and 
screenings, including diabetes and mammography; staff also identified attendees who were 
overdue for a Pap test and verbally recruited eligible women for the project. Those agreeing 
to participate were given an IRB-approved cover letter explaining the purpose of the project 
and an eight-question survey to complete. The survey assessed sociodemographics, primary 
barrier(s) to screening, and motivation(s) for requesting a Pap test. After completing the 
survey, women received a $20 gift card for their time and were given the opportunity to 
receive a Pap test from health department nurse practitioners at no cost.
Patient Navigation and Follow-up Care
Pap test results and information on screening recommendations were mailed to each 
participant. Letters detailing abnormal results requested that women call the health 
department within 4 working days to schedule a follow-up appointment; non-responders 
were subsequently sent a certified letter. Health department staff conducted home visits for 
non-responders if their results indicated advanced dysplasia or precancerous or cancerous 
cells. Women requiring follow-up care were offered navigation, including assistance with 
scheduling diagnostic testing appointments and enrollment in the cancer screening program, 
if needed. The health department provided all navigation; follow-up care was provided by 
health department–contracted gynecologic providers.
Statistical Analysis
Data analyses consisted of basic frequencies for the eight-item survey, Pap testing results, 
and reported follow-up care for those with abnormal results. To determine whether 
differences existed between women with an abnormal result and those with a negative result, 
bivariate analyses were conducted. This analysis included basic sociodemographic 
characteristics, reported barriers to Pap testing, and self-reported motives for Pap testing at 
WHD. All analyses were conducted in 2014 using SPSS, version 22.0.
Results
During WHD events, 317 women who self-reported to be rarely or never screened for 
cervical cancer participated in the project. As presented in Table 1, the majority of women 
were aged 26–55 years (64.1%), with a mean age of 42.1 (SD=13.6) years. Project 
participants, in comparison to U.S. Census estimates (2009–2013) for women in the 
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catchment area, reported higher education levels (84% vs 75.7%, high school degree or 
higher) and lower household incomes (57.7% vs 42.2%, income of ≤$25,000).30
As shown in Table 2, the most commonly reported Pap testing barriers were cost (28.4%); 
lack of perceived need for screening (25.6%); and lack of transportation (11.0%). Other 
reported barriers related to fear of test results (9.1%); lack of time or not taking the time to 
engage in screening (8.8%); and dislike of the screening process, which some women 
perceived to cause pain, discomfort, fear, or embarrassment (5.7%). In addition, almost 8% 
of participants reported other screening barriers (e.g., preference for a female healthcare 
provider, lack of parental support); three-quarters of women indicated one primary barrier to 
screening (75.4%).
The most commonly reported motives for Pap testing at WHD were referrals from a 
healthcare provider or health department (25.6%); experiencing problems or symptoms 
(17.0%); and the perceived need to have a Pap test (11.7%). Women also reported that 
having a family member or friend with a previous cancer experience (9.8%) and receiving a 
gift card (8.5%) motivated their participation; almost all women reported one primary 
motive for participating in screening (90.9%).
Nearly 80% of women received a negative result (i.e., negative for intraepithelial lesion or 
malignancy). However, as presented in Table 3, 68 women (21.7%) received an abnormal 
test result. The most frequent abnormal results were atypical squamous cells of 
undetermined significance (22 women, 7.0%) and low-grade squamous intraepithelial 
lesions (21 women, 6.7%); one woman tested positive for squamous cell carcinoma. Health 
department Pap testing logs indicated that 16 women with abnormal results received some 
form of navigation or follow-up care, consisting of colposcopy or gynecologist referrals 
(five women); colposcopy (ten women): or loop electrosurgical excision procedure (one 
woman). Bivariate analyses determined no significant differences between Pap test result 
groups (i.e., negative or positive) in regard to demographics, with the exception of age 
(p=0.001). Women aged 18–25 years were more likely to receive positive test results than 
women aged 45–65 years; women aged 26–45 years also were more likely to receive a 
positive test result than women aged 56–65 years. Cost was found to be the only significant 
screening barrier (p=0.034); those with negative results were more likely to report cost as a 
primary barrier. No reported motivators reached statistical significance.
Discussion
The WHD events allowed rarely or never-screened women to receive much-needed Pap 
testing services. Notably, more than 20% of participants had an abnormal Pap test result, 
with one woman being diagnosed with cervical cancer. The significant findings regarding 
age and screening results mirror previous findings, as abnormal results tend to be more 
common among younger women owing to the higher prevalence of human 
papillomavirus.33,34 Although younger women are more likely to have abnormal results, 
women older than 30 years are more likely to develop cervical cancer.35 Women older than 
30 years should continue to be targeted because of their increased risk for invasive disease. 
Nearly 25% of women with abnormal screening results received navigation to follow-up 
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care. Lack of appropriate follow-up care after an abnormal screening has been previously 
documented among women enrolled in public programs (e.g., Medicaid, NBCCEDP), with 
follow-up rates ranging from 10.1% to 31.5% in a recent study involving Medicaid 
enrollees.34,36 Women’s eligibility for such programs frequently changes and may lead 
women to receive follow-up care elsewhere, thus not allowing for accurate documentation of 
services.34 Some women may also choose to forego follow-up services even if navigation is 
offered. Moreover, those with less serious test results may only need more-frequent 
screenings rather than further navigation.35 In this case, follow-up information may not have 
been explicitly documented. Of note, many of the women with more-serious abnormalities 
were among those successfully navigated for additional care.
Many of the Pap testing barriers reported by WHD participants (e.g., cost, lack of perceived 
need for screening, lack of transportation) reinforced previous findings regarding screening 
barriers in Appalachia.9,20,37,38 Screening costs were found to be a significant barrier for 
women in the project, despite their testing outcome. With more than half reporting an annual 
household income of less than $25,000, this finding reflects previous results suggesting that 
costs remain a primary barrier for rural women.8,9 Interestingly, women with negative Pap 
test results were significantly more likely to report cost as a primary barrier to screening; 
further investigation of this unique finding is warranted.
Of particular importance is the lack of perceived need for screening among this population. 
Decreased risk perceptions may contribute to the belief that cervical cancer screening is only 
needed when physical symptoms occur, which is a common misperception among rural and 
Appalachian women.20,38–40 However, this belief is also found in other populations; in a 
recent systematic review, nearly 12% of included studies reported results involving the 
belief that screening is only needed in the presence of physical symptoms.41 One of the 
primary motives for Pap testing in this project was the occurrence of problems or symptoms; 
this suggests that further education about cervical cancer, specifically established risk 
factors and symptoms, may be warranted.38,40,42
As previously noted, women in the project reported lower household incomes, yet higher 
education levels compared with Census data for the catchment area. Higher education levels 
have been found to be correlated with participation in Pap testing across varying 
populations.43 Despite higher educational attainment, women in the project may have been 
guideline discordant prior to WHD because of reported screening barriers, such as cost and 
lack of perceived susceptibility. WHD events may have helped women overcome these 
barriers by providing accurate information on cervical cancer risk, free onsite Pap testing 
services, and participation incentives. Among this sample of guideline-discordant women, 
three fourths reported only one primary barrier to screening, suggesting that minimal but 
strategic effort may be needed to remove these barriers. Increased promotion of existing 
screening programs through targeted partnerships and special events are viable strategies to 
encourage participation in cervical cancer screenings.25,44 Special events, such as WHD, 
provide health-related education to attendees and facilitate the removal of screening 
barriers.45 WHD events also serve as a sustainable model for increasing the reach of existing 
screening programs by promoting awareness and uptake of cervical cancer screening with 
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very few associated costs. Beyond incentive funds, existing staff and KWCSP funding were 
redistributed to cover event costs.
Notably, many participants were established health department patients and had a medical 
home in which to receive recommended screenings, yet they were guideline discordant. 
Although an increase in baseline screening rates cannot be determined, findings suggest that 
women participated in screenings that they were otherwise not engaging in; women may 
have remained guideline discordant without the removal of screening barriers provided by 
the WHD events. Thus, rural Appalachian women who are guideline discordant may need 
targeted inventions, such as special events, in order to encourage participation in routine 
cervical cancer screenings. According to the Community Preventive Services Task Force, 
there are still research gaps regarding effective cervical cancer screening intervention 
strategies.46 Although special events have been commonly used to promote cancer 
screening, there remains insufficient evidence to determine their true impact on screening 
rates.45 The study findings contribute to the existing literature by providing additional 
evidence that targeted interventions, such as special events, can encourage guideline-
discordant women to participate in cervical cancer screenings.
Limitations
Owing to the cross-sectional nature of the survey, no causal inference can be established 
between barriers and motives. Because this study used a convenience sample, project 
findings may not be generalizable to women residing in other parts of rural Appalachia. 
Selection bias may also be present, as women who participated in the project may differ 
from rarely and never-screened women who did not participate. The participation rate could 
not be determined because neither data regarding the number of women eligible for 
participation nor the number of women who refused to participate were collected. Pap 
testing history was self-reported; thus, reported years since last Pap test may be inaccurate.
Conclusions
As advocated by Mays and Scutchfield,47 coordinated, well-defined partnerships are needed 
to improve public health outcomes. The academic–community partnership between KRDHD 
and RCPC is an example of a successful public health collaboration that led to increased 
promotion of an existing screening program and uptake of Pap testing services among rarely 
and never-screened women in Appalachian Kentucky. Such collaborations will be needed in 
the future to continue addressing cancer disparities in Appalachia and beyond.
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Table 1
Participant Characteristics (N=317)
Characteristic n (%)
Age (years)
 18–25 51 (16.1)
 26–45 120 (37.9)
 46–55 83 (26.2)
 56–65 63 (19.9)
Education (n=308)
 <High school 49 (15.9)
 High school graduate or GED 168 (54.5)
 ≥Some college 91 (29.5)
Income (n=310)
 <$25,000 179 (57.7)
 $25,000–$50,000 72 (23.2)
 >$50,000 59 (19.0)
Number of people in household (n=316)
 1–3 219 (69.3)
 ≥4 97 (30.7)
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Table 2
Reported Barriers and Motives for Pap Testing (N=317)
Barriers and motives n (%)
Primary barrier(s) to Pap testinga
 Could not afford it 90 (28.4)
 No transportation 35 (11.0)
 Didn’t feel I needed it 81 (25.6)
 Husband would not let me 2 (0.6)
 Afraid to hear the results 29 (9.1)
 Did not have the time/take the time 28 (8.8)
 Do not like it (i.e., painful, uncomfortable, afraid, embarrassing) 18 (5.7)
 Other 24 (7.6)
Primary motivation(s) for requesting Pap testa
 Referred by healthcare provider/health department 81 (25.6)
 Received information from the RCPC 18 (5.7)
 Change in marital status 12 (3.8)
 Having problems (symptoms) 54 (17.0)
 Family member or friend with cancer experience 31 (9.8)
 Ad in newspaper 5 (1.6)
 Time for Pap test/knew I needed to get it done 37 (11.7)
 Birth control 20 (6.3)
 Family/friend encouraged me 17 (5.4)
 Gift card/Door prize 27 (8.5)
 Other 33 (10.4)
a
Multiple responses provided; percentages may add up to ≥100% RCPC, Rural Cancer Prevention Center.
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Table 3
Participant Pap Test Results (n=314)
Result n (%)
Negative 246 (78.3)
Abnormal 68 (21.7)
 Atypical glandular cells 4 (1.3)
 Atypical squamous cells of uncertain significance (ACS-US) 22 (7.0)
 Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) 10 (3.2)
 Low-grade squamous intraepithelial lesions (LSIL: CIN I, HPV) 21 (6.7)
 High-grade squamous intraepithelial lesions (HSIL: CIN II, CIN III, CIS) 10 (3.2)
 Squamous cell carcinoma 1 (0.3)
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